Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Befotertinib Plus Chemotherapy With an MRD-guided Adaptive Strategy for Treatment Escalation and Response Optimization in EGFR-mutated NSCLC Patients

NCT07709585 is registered in ClinicalTrials.gov with Guangzhou University of Traditional Chinese Medicine as lead sponsor.

NCT NCT07709585
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07709585 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Befotertinib Plus Chemotherapy With an MRD-guided Adaptive Strategy for Treatment Escalation and Response Optimization in EGFR-mutated NSCLC Patients
Lead sponsor
Guangzhou University of Traditional Chinese Medicine
Phase
Phase 2
Overall status
Not yet recruiting
Start date
July 5, 2026
Completion date
July 31, 2030
Enrollment
124 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced non-small cell lung cancer (nsclc), egfr exon 19 deletion mutation, egfr exon 21 l858r mutation, egfr exon 21 mutation